Clinical Trials Logo

Spinal Muscular Atrophy clinical trials

View clinical trials related to Spinal Muscular Atrophy.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT04159987 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®

SMAII
Start date: February 25, 2020
Phase: N/A
Study type: Interventional

SPINRAZA® (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).

NCT ID: NCT04139343 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

Motor Unit Number Estimation (MUNE) in Adults With Spinal Muscular Atrophy (SMA)

Start date: August 10, 2018
Phase:
Study type: Observational

The primary objective of this research protocol is to study and follow the course of motor neuron loss in individuals with spinal muscular atrophy (SMA) using the electrophysiological technique of motor unit number estimation (MUNE). This study is based on the hypothesis that the electrophysiological technique of motor unit number estimation (MUNE) and compound muscle action potential (CMAP) provide sensitive indicators to assess the severity and progression of disease in adults with SMA.

NCT ID: NCT03032172 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

Jewelfish
Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA) previously enrolled in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previously treated with nusinersen, olesoxime or AVXS-101.

NCT ID: NCT02386553 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NURTURE
Start date: May 18, 2015
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.